Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy
Open Access
- 6 February 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 104 (5), 357-370
- https://doi.org/10.1093/jnci/djr533
Abstract
Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are among the most serious and life-threatening late adverse effects experienced by the growing number of cancer survivors worldwide and are due in part to radiotherapy. The National Council on Radiation Protection and Measurements (NCRP) convened an expert scientific committee to critically and comprehensively review associations between radiotherapy and SMNs and CVD, taking into account radiobiology; genomics; treatment (ie, radiotherapy with or without chemotherapy and other therapies); type of radiation; and quantitative considerations (ie, dose–response relationships). Major conclusions of the NCRP include: 1) the relevance of older technologies for current risk assessment when organ-specific absorbed dose and the appropriate relative biological effectiveness are taken into account and 2) the identification of critical research needs with regard to newer radiation modalities, dose–response relationships, and genetic susceptibility. Recommendation for research priorities and infrastructural requirements include 1) long-term large-scale follow-up of extant cancer survivors and prospectively treated patients to characterize risks of SMNs and CVD in terms of radiation dose and type; 2) biological sample collection to integrate epidemiological studies with molecular and genetic evaluations; 3) investigation of interactions between radiotherapy and other potential confounding factors, such as age, sex, race, tobacco and alcohol use, dietary intake, energy balance, and other cofactors, as well as genetic susceptibility; 4) focusing on adolescent and young adult cancer survivors, given the sparse research in this population; and 5) construction of comprehensive risk prediction models for SMNs and CVD to permit the development of follow-up guidelines and prevention and intervention strategies.Keywords
This publication has 201 references indexed in Scilit:
- Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphomaNature Medicine, 2011
- Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologistsCancer Causes & Control, 2010
- Secondary malignant neoplasms after Wilms tumor: An international collaborative studyInternational Journal of Cancer, 2010
- A Transcriptional Signature and Common Gene Networks Link Cancer with Lipid Metabolism and Diverse Human DiseasesCancer Cell, 2010
- Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case‐control studyInternational Journal of Cancer, 2009
- Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologistsBreast Cancer Research and Treatment, 2009
- Unilateral and Bilateral Breast Cancer in Women Surviving Pediatric Hodgkin's DiseaseInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Risk of Second Malignancies After Adjuvant Radiotherapy for Breast Cancer: A Large-Scale, Single-Institution ReviewInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic LeukemiaJAMA, 2007
- Radiation‐induced sarcomas after radiotherapy for breast carcinomaCancer, 2005